

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **160 Health International Limited**

### **健康 160 国际有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2656)**

#### **VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE**

This announcement is made by 160 Health International Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Company of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, leveraging its integrated “Platform + AI Agent + Operation” model, the Group is progressively deploying a “Medical Digital Staff” system to medical institutions to facilitate the use of AI agents, exemplified by OpenClaw, within medical scenarios. Specifically, the Group integrates AI agents throughout the entire pre-consultation, consultation and post-consultation process. Through multi-agent collaboration, these agents are applied to patient management, health education, and operation of high-value health services, as well as automated medical record generation, intelligent medical insurance calculation, and departmental ledger management. This initiative aims to alleviate the administrative burden on medical staff, enabling them to focus more on their core clinical duties.

In parallel with its external empowerment initiatives, the Group has fully integrated AI agents into its internal operations. AI agents have been implemented across product research and development, content production, and customer service systems, resulting in a reduction of the product iteration cycle by more than 60%. Meanwhile, the Group has completed the deployment of OpenClaw and continues to optimize its related applications. The improvements in internal efficiency have also significantly accelerated the deployment and delivery speed for medical institutions.

The Group consistently adheres to a “security-first” principle. All AI agents, whether deployed externally or internally, undergo comprehensive end-to-end security hardening carried out by its dedicated in-house technical team, ensuring the safe and stable operation of our systems. In the future, leveraging its authentic doctor-patient interaction scenarios and mature platform-based operational capabilities, the Group will strive to explore the advanced applications of AI agents, such as OpenClaw, within the medical and healthcare sectors, with the goal of creating long-term value for its shareholders.

By order of the Board  
**160 Health International Limited**  
**Mr. LUO Ningzheng**  
*Chairman of the Board, Executive Director  
and Chief Executive Officer*

Hong Kong, March 11, 2026

*As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. LIU Haibin and Ms. SUN Meng as non-executive Directors; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.*